iCAD, Inc. (NASDAQ:ICAD – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.51 and traded as high as $1.68. iCAD shares last traded at $1.56, with a volume of 103,749 shares trading hands.
Wall Street Analyst Weigh In
Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, August 22nd.
Check Out Our Latest Analysis on iCAD
iCAD Stock Performance
iCAD (NASDAQ:ICAD – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The technology company reported ($0.07) EPS for the quarter. The business had revenue of $5.03 million during the quarter. iCAD had a negative net margin of 15.67% and a negative return on equity of 13.59%.
Institutional Investors Weigh In On iCAD
Large investors have recently added to or reduced their stakes in the company. Salem Investment Counselors Inc. acquired a new stake in iCAD in the first quarter valued at $119,000. Perritt Capital Management Inc lifted its position in shares of iCAD by 14.2% during the second quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock worth $208,000 after purchasing an additional 19,917 shares during the last quarter. First Eagle Investment Management LLC increased its holdings in iCAD by 3.2% in the first quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company’s stock valued at $1,129,000 after buying an additional 22,000 shares during the last quarter. AMH Equity Ltd acquired a new stake in iCAD during the first quarter valued at approximately $207,000. Finally, Virtu Financial LLC raised its stake in iCAD by 55.6% during the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after buying an additional 7,604 shares in the last quarter. 24.61% of the stock is owned by institutional investors and hedge funds.
About iCAD
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Stories
- Five stocks we like better than iCAD
- Using the MarketBeat Stock Split Calculator
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What is the NASDAQ Stock Exchange?
- MarketBeat Week in Review – 9/16 – 9/20
- 3 Small Caps With Big Return Potential
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.